Principal Scientist, Formulation Development H-1B salaries
8 labor condition applications from 7 employers in FY2024–FY2026 · occupation Chemists
$139,700median salary
$114,88925th percentile
$156,25075th percentile
8certified LCAs
Employers sponsoring Principal Scientist, Formulation Development jobs
| Employer | LCAs | Median | Range |
|---|---|---|---|
| Hikma Pharmaceuticals USA Inc. | 2 | $104,562 | |
| Antares Therapeutics, Inc. | 1 | $190,000 | |
| Cerevel Therapeutics, LLC | 1 | $130,000 | |
| PTC Therapeutics, Inc. | 1 | $149,400 | |
| Abbvie Bioresearch Center Inc. | 1 | $155,000 | |
| Pfizer Inc. | 1 | $118,331 | |
| AbbVie Inc. | 1 | $160,000 |
Salaries by city
- Somerset, NJ 2 · $145,000
- Columbus, OH 2 · $104,562
- Andover, MA 1 · $118,331
- Boston, MA 1 · $190,000
- Cambridge, MA 1 · $155,000
- Bridgewater, NJ 1 · $149,400
Related job titles
| Job title | LCAs | Median salary |
|---|---|---|
| Chemist | 387 | $75,005 |
| Scientist III | 138 | $90,000 |
| Quality Control Chemist | 111 | $69,923 |
| Analytical Chemist | 101 | $80,000 |
| QC Chemist | 80 | $69,202 |
| Formulation Scientist | 62 | $82,653 |
| Analytical Scientist | 51 | $95,938 |
| Senior Chemist | 50 | $93,250 |
| Research Chemist | 49 | $91,893 |
| Chemist II | 44 | $76,000 |
| R&D Scientist | 43 | $95,784 |
| Quality Assurance Chemist | 39 | $72,125 |
| Research Associate Chemistry | 34 | $84,200 |
| Pharmaceutical Chemist - Quality Control | 31 | $65,000 |
| Senior Scientist, Chemistry | 28 | $117,000 |
| Process Development Sr Scientist | 25 | $133,112 |
Questions and answers
What is the H-1B salary for a Principal Scientist, Formulation Development?
The median salary on certified H-1B LCAs for Principal Scientist, Formulation Development is $139,700; the middle half of offers ranges from $114,889 to $156,250 (8 certified filings).
Which companies sponsor H-1B visas for Principal Scientist, Formulation Development jobs?
The largest sponsors are Hikma Pharmaceuticals USA Inc., Antares Therapeutics, Inc., Cerevel Therapeutics, LLC, PTC Therapeutics, Inc., Abbvie Bioresearch Center Inc..